S
Silvia Beatriz Boscardin
Researcher at University of São Paulo
Publications - 83
Citations - 2489
Silvia Beatriz Boscardin is an academic researcher from University of São Paulo. The author has contributed to research in topics: Immune system & Antigen. The author has an hindex of 23, co-authored 65 publications receiving 2156 citations. Previous affiliations of Silvia Beatriz Boscardin include University of Antofagasta & Rockefeller University.
Papers
More filters
Journal ArticleDOI
Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses.
Silvia Beatriz Boscardin,Julius C. R. Hafalla,Revati F. Masilamani,Alice O. Kamphorst,Henry Zebroski,Urvashi Rai,Alexandre Morrot,Fidel Zavala,Ralph M. Steinman,Ruth S. Nussenzweig,Michel C. Nussenzweig +10 more
TL;DR: It is concluded that antigen targeting to DCs combined with a maturation stimulus produces broad-based and long-lived T cell help for humoral immune responses.
Journal ArticleDOI
The circumsporozoite protein is an immunodominant protective antigen in irradiated sporozoites
Kota Arun Kumar,Gen Ichiro Sano,Silvia Beatriz Boscardin,Ruth S. Nussenzweig,Michel C. Nussenzweig,Fidel Zavala,Victor Nussenzweig +6 more
TL;DR: Although hundreds of other Plasmodium genes are expressed in sporozoites and EEFs, CS is a dominant protective antigen and sterile immunity could be obtained by immunization of CS transgenics with three doses of IrSp.
Journal ArticleDOI
Identification of antigen-presenting dendritic cells in mouse aorta and cardiac valves
Jae-Hoon Choi,Yoonkyung Do,Cheolho Cheong,Hyein Koh,Silvia Beatriz Boscardin,Yong-Seok Oh,Leonia Bozzacco,Christine Trumpfheller,Chae Gyu Park,Ralph M. Steinman +9 more
TL;DR: Results indicate that bona fide DCs are a constituent of the normal aorta and cardiac valves and cross-presented two different protein antigens on MHC class I to CD8+ TCR transgenic T cells.
Journal ArticleDOI
Adjuvants: Classification, Modus Operandi, and Licensing
Juliana de Souza Apostólico,Victória Alves Santos Lunardelli,Fernanda Caroline Coirada,Silvia Beatriz Boscardin,Daniela Santoro Rosa +4 more
TL;DR: The most well known adjuvants used in experimental and clinical settings are described based on their main mechanisms of action and the requirements for licensing new vaccine formulations are highlighted.
Journal ArticleDOI
Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and αDEC-CSP in non human primates
Kavita Tewari,Barbara J. Flynn,Silvia Beatriz Boscardin,Kathrin Kastenmueller,Andres M. Salazar,Charles A. Anderson,Velmurugan Soundarapandian,Adriana Ahumada,Tibor Keler,Stephen L. Hoffman,Michel C. Nussenzweig,Ralph M. Steinman,Robert A. Seder +12 more
TL;DR: Data showing that poly(I:C) is an effective adjuvant for inducing potent antibody and Th1 immunity with CSP based vaccines offers a potential alternative to the existing protein based pre-erythrocytic vaccines are shown.